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ABSTRACT
Organic anion transporter-1 (OAT1) mediates the body’s dispo-
sition of a diverse array of environmental toxins and clinically
important drugs. Therefore, understanding the regulation of this
transporter has profound clinical significance. We had previously
established that OAT1 undergoes constitutive internalization from
and recycling back to the cell surface and that acute activation of
protein kinase C (PKC) inhibits OAT1 activity by reducing OAT1
cell-surface expression through accelerating its internalization
from cell surface to intracellular compartments. However, the
underlying mechanisms are poorly understood. In the current
study, we provide novel evidence that acute activation of PKC
significantly enhances OAT1 ubiquitination both in vitro and ex
vivo. We further show that ubiquitination of cell-surface OAT1
increases in cells transfected with dominant negative mutant of
dynamin-2, a maneuver blocking OAT1 internalization, which
suggests that OAT1 ubiquitination proceeds before OAT1 in-
ternalization. Mass spectroscopy has revealed that ubiquitination
of OAT1 consists of polyubiquitin chains, primarily through lysine
48 linkage. Transfection of cells with the dominant negative
mutant of ubiquitin Ub-K48R, which prevents the formation of
Lys48-linked polyubiquitin chains, abolishes PKC-stimulated
OAT1 ubiquitination and internalization. Together, our findings
demonstrate for the first time that Lys48-linked polyubiquitination
is essential for PKC-regulated OAT1 trafficking.
Introduction
The organic anion transporter (OAT) family mediates the
body’s disposition of a diverse array of environmental toxins
and clinically important drugs, including anti-HIV therapeu-
tics, antitumor drugs, antibiotics, antihypertensives, and
anti-inflammatories (You, 2002; Dantzler and Wright, 2003;
Srimaroeng et al., 2008; Ahn and Nigam, 2009; VanWert
et al., 2010). Therefore, understanding the regulation of these
transporters has profound clinical significance.
Ten OATs (OAT1–10) have been cloned, and their expres-
sions have been identified in distinct tissues and cell
membranes. In the kidney, OAT1 and OAT3 use a tertiary
transport mechanism to move organic anions across the
basolateral membrane into the proximal tubule cells for
subsequent exit across the apical membrane into the urine for
elimination. Through this tertiary transport mechanism, Na1
/K1-ATPase maintains an inwardly directed (blood-to-cell)
Na1 gradient. The Na1 gradient then drives a sodium
dicarboxylate cotransporter, sustaining an outwardly directed
dicarboxylate gradient that is used by a dicarboxylate/organic
anion exchanger—namely, OAT—to move the organic anion
substrate into the cell. This cascade of events indirectly links
organic anion transport to metabolic energy and the Na1
gradient, allowing the entry of a negatively charged substrate
against both its chemical concentration gradient and the
electrical potential of the cell (You, 2002; Dantzler andWright,
2003; Srimaroeng et al., 2008; Ahn and Nigam, 2009; VanWert
et al., 2010).
All of the cloned OATs share several common structural
features, including 12 transmembrane domains flanked by
intracellular amino and carboxyl termini, multiple glycosyl-
ation sites localized in the first extracellular loop, and
multiple potential phosphorylation sites. Investigations by
our laboratory on the structure–function relationship of OATs
have revealed that glycosylation is necessary for the targeting
of these transporters to the plasma membrane (Tanaka et al.,
2004).
The amount of OATs at the cell surface is critical for their
drug transport activity. We previously showed that members
of OAT family constitutively internalize from and recycle back
to the cell surface, and that inhibition of OAT activity by acute
activation of protein kinase C (PKC) results from an
accelerated internalization of these transporters from the cell
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surface to intracellular compartments without affecting the
total expression of the transporters (Zhang et al., 2008).
However, the effect of the mechanisms of PKC on OAT
internalization and function is largely unknown. PKC-
induced direct phosphorylation has been reported for other
membrane proteins, yet our results showed that a range of
PKC activators failed to elevate the phosphorylation level of
OATs under various experimental conditions (You et al.,
2000). This suggests that direct phosphorylation of OATs is
unlikely to be the cause for PKC-induced inhibition of OAT
activity.
Recently, modification of receptors and channels by ubiq-
uitin conjugation has emerged as the major regulatory
mechanism of internalization, intracellular sorting, and
turnover of these membrane proteins (Miranda et al., 2005;
Kumar et al., 2007; Zhou et al., 2007; Varghese et al., 2008;
Bomberger et al., 2009). Ubiquitin moiety can be recognized
by the components of plasma membrane internalization and
endosomal sorting machinery.
Ubiquitin is a highly conserved 76-amino-acid protein
that forms an isopeptide bond between its C-terminal
glycine and a lysine residue on the target protein. Each
ubiquitin moiety harbors seven lysine residues (Lys6,
Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), allowing
for the formation of ubiquitin chains linked through its
internal lysine residues. Therefore, a substrate can be
modified by different types of ubiquitin conjugation: mono-
ubiquitination (conjugation of one single ubiquitin to one
single lysine on the substrate), multiubiquitination (conju-
gation of several monoubiquitin molecules to multiple lysine
residues on the substrate), and polyubiquitination (ex-
tended polyubiquitin chain). In addition, a polyubiquitin
chain can bear different linkages such as Lys48 linkage
(Lys48 in the ubiquitin serves as a base for chain elongation)
and Lys63 linkage (Lys63 in the ubiquitin serves as a base
for chain elongation). It has been shown that different types
and linkages of ubiquitination have different physiologic
outcomes for the ubiquitinated substrate (Kolodziejski
et al., 2002; Miranda et al., 2005; Kumar et al., 2007; Zhou
et al., 2007; Bomberger et al., 2009). Our study investi-
gated the role of ubiquitination in PKC-regulated OAT1
trafficking.
Materials and Methods
Membrane impermeable biotinylation reagent NHS-SS-biotin and
streptavidin agarose beads were purchased from Pierce (Rockford,
IL). COS-7 cells and Dynamin (Dyn)-2/K44A mutant were purchased
from the American Type Culture Collection (Manassas, VA). cDNA for
hemagglutinin (HA)-tagged mutant ubiquitin HA-UbDG was gener-
ously provided by Dr. N. Tony Eissa of the Department of Medicine,
Baylor College of Medicine, Houston, TX. cDNAs for HA-tagged wild-
type ubiquitin and HA-tagged ubiquitin mutants HA-K48R and HA-
K63R were generously provided by Dr. Cam Patterson of the Carolina
Cardiovascular Biology Center, University of North Carolina (Chapel
Hill, NC). Mouse anti-myc antibody (9E10) and mouse anti-HA
antibody 12CA5 were purchased from Roche Diagnostics Corporation
(Indianapolis, IN). Mouse anti-ubiquitin antibody P4D1 was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-
ubiquitin antibody FK2 was purchased from Enzo Life Sciences
(Farmingdale, NY). PKC activator phorbol 12-myristate 13-acetate
(PMA) and all other reagents were purchased from Sigma-Aldrich (St.
Louis, MO).
Cell Cultures. COS-7 cells stably expressing human OAT1
(tagged with epitope myc at its carboxyl terminus for immunodetec-
tion) (Zhang et al., 2008) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 0.2 mg/ml G418, 10%
fetal bovine serum, penicillin/streptomycin (100 U/ml), and glucose
(100 mg/ml).
Ubiquitination Assay. Cells expressing OAT1-myc were treated
with dimethyl sulfoxide (DMSO) or 1 mM PMA at 37°C for indicated
time periods. Treated cells were lysed with lysis buffer I (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM
EDTA, and 1 mM NaF) freshly added with 1% of proteinase inhibitor
cocktail and 20 mM N-ethylmaleimide (a deubiquitination inhibitor).
OAT1 was then immunoprecipitated with anti-myc antibody, followed
by immunoblotting with anti-ubiquitin antibody P4D1 or anti-myc
antibody 9E10.
Preparation of Rat Kidney Slices. Male Sprague-Dawley rats
were euthanized by CO2 inhalation, and the kidneys were immedi-
ately placed into freshly oxygenated ice-cold saline. Tissue slices
(,0.5 mm; 5–10 mg wet weight) were cut with a Stadie-Riggs
microtome and maintained in ice-cold modified Cross and Taggart
saline (95mMNaCl, 80mMmannitol, 5 mMKCl, 0.74mMCaCl2, and
9.5 mM Na2PO4, pH 7.4) for ubiquitination studies.
Cell Surface Biotinylation. The cell-surface expression level of
OAT1 was examined using the membrane-impermeable biotinylation
reagent NHS-SS-biotin. Cells were plated in six-well plates. Each well
of cells was incubated with 1 ml of NHS-SS-biotin (0.5 mg/ml in
phosphate-buffered saline [PBS]) in two successive 20-minute
incubations on ice with very gentle shaking. The reagent was freshly
prepared each time. After biotinylation, each well was briefly rinsed
with 3 ml of PBS/CM containing 100 mM glycine then incubated with
the same solution for 30 minutes on ice to ensure complete quenching
of the unreacted NHS-SS-biotin. The cells were then lysed on ice for 1
hour in 400 ml of lysis buffer (10mMTris, 150mMNaCl, 1 mMEDTA,
0.1% SDS, 1% Triton X-100 with 1/100 protease inhibitor cocktail).
The cell lysates were cleared by centrifugation at 16,000g at 4°C. We
then added 50 ml of streptavidin-agarose beads to the supernatant to
isolate cell membrane proteins. OAT1 was detected in the pool of
surface proteins by immunoblotting using an anti-myc antibody 9E10.
To determine ubiquitinated OAT1 in the biotinylated protein
fraction, cell-surface proteins were biotinylated. OAT1 was immuno-
precipitated with anti-myc antibody. Immunoprecipitated proteins
were eluted from the beads with 1% SDS (37°C, 15 minutes). Next,
SDS was diluted to 0.1%, and the eluted OAT1 proteins were
incubated with streptavidin-agarose beads, followed by immunoblot-
ting using anti-ubiquitin antibody P4D1 or anti-myc antibody.
Internalization Assay. For the internalization assay, we fol-
lowed the procedure previously established in our laboratory (Zhang
et al., 2008). OAT1-expressing cells underwent biotinylation with 0.5
mg/ml sulfo-NHS-SS-biotin at 4°C. Following biotinylation, OAT1
internalization was initiated by incubating the cells (37°C) in PBS
containing either 1 mMPMA or vehicle for designated periods of time.
Residual cell-surface biotin was stripped by incubating cells 3 times
for 20 minutes with freshly prepared 50 mMMesNa in NT buffer (150
mMNaCl, 1 mM EDTA, 0.2% bovine serum albumin, 20 mM Tris, pH
8.6). Cells were lysed in lysis buffer with protease inhibitor cocktail.
Biotinylated (internalized) proteins were separated from nonbiotiny-
lated proteins by streptavidin pull-down from equivalent amounts of
cellular proteins, followed by immunoblotting with anti-myc antibody.
Purification of Ubiquitinated OAT1 by Sequential Immu-
noprecipitation. Six 10-cm-diameter dishes of COS-7 cells express-
ing OAT1 were treated with 1 mM PMA for 30 minutes at 37°C.
Treated cells were solubilized with lysis buffer I with 3% proteinase
inhibitor cocktail and 40 mM N-ethylmaleimide. The total cell lysate
was precleared with protein G-agarose for 2 hours at 4°C, followed by
immunoprecipitation with anti-myc antibody that was cross-linked to
protein G beads with dimethyl pimelimidate (Pierce). After an
extensive wash with lysis buffer I containing 500 mM NaCl, the
immunoprecipitated proteins were eluted with 1% SDS and
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immunoprecipitated again with anti-ubiquitin antibody FK2, which
was cross-linked to protein G beads with dimethyl pimelimidate.
After the second immunoprecipitation, 10% of precipitated proteins
were analyzed by immunoblotting with anti-ubiquitin antibody P4D1
or anti-myc antibody, and 90% by Coomassie Blue staining.
Protein Identification by Liquid Chromatography–Tandem
Mass Spectrometry. The gel bands of interest were reduced,
carboxymethylated with iodoacetamide, digested with trypsin. Pep-
tides were extracted, solubilized in 0.1% trifluoroacetic acid, and
analyzed by nano-liquid chromatography–tandemmass spectrometry
(LC-MS/MS) using a rapid separation liquid chromatography system
(Dionex, Sunnyvale, CA) interfaced with a Velos-LTQ-Orbitrap
(Thermo Fisher Scientific, San Jose, CA). Samples were loaded onto
a self-packed 100 mm  2 cm trap packed with Magic C18AQ, 5-mm
200 A (Michrom Bioresources Inc., Auburn, CA) and washed with
buffer A (0.2% formic acid) for 5 minutes with flow rate of 10 ml/min.
The trap was brought in line with the homemade analytical column
(Magic C18AQ, 3 mm 200 A, 75 mm  50 cm), and peptides were
fractionated at 300 nl/min with a 90-minute linear gradient of 2 to
45% buffer B (0.2% formic acid, acetonitrile). Mass spectrometry data
were acquired using a data-dependent acquisition procedure, with
a cyclic series of a full scan acquired in Orbitrap with resolution of
60,000 followed by MS/MS scans (acquired in linear ion trap) of 20
most intense ions with a repeat count of two and the dynamic
exclusion duration of 60 seconds.
The LC-MS/MS data were searched against the ENSEMBL human
database using a local version of the Global Proteome Machine (GPM
USB; Beavis Informatics Ltd, Winnipeg, MB, Canada) with carbami-
doethyl on cysteine as the fixed modification and ubiquitination on
lysine (1114 Da) as well as oxidation of methionine and tryptophan as
the variable modifications using a 10-ppm precursor ion tolerance and
a 0.4-Da fragment ion tolerance. Polyubiquitin sites were identified on
ubiquitin lysine residues.
Electrophoresis and Immunoblotting. Protein samples were
resolved on 7.5% SDS-PAGE minigels and electroblotted on to
polyvinylidene difluoride membranes. The blots were blocked for 1
hour with 5% nonfat dry milk in PBS–0.05% Tween-20, washed, and
incubated for 1 hour at room temperature with appropriate primary
antibodies followed by horseradish peroxidase–conjugated secondary
antibodies. The signals were detected by the SuperSignal West Dura
Extended Duration Substrate kit (Pierce). Nonsaturating, immuno-
reactive protein bands were quantified by scanning densitometry with
the FluorChem 8000 imaging system (Alpha Innotech Corporation,
San Leandro, CA).
Data Analysis. Each experiment was repeated a minimum of
three times. The statistical analysis was from multiple experiments.
Statistical analysis was performed using Student’s paired t tests. P,
0.05 was considered statistically significant.
Results
PKC-Induced Ubiquitination of OAT1 by Endoge-
nous Ubiquitin. To examine whether OAT1 undergoes
ubiquitination, COS-7 cells stably expressing OAT1 were
treated with or without PMA, a PKC activator, for different
periods of time. OAT1 was then immunoprecipitated by anti-
myc antibody (myc was tagged to OAT1), followed by
immunoblotting with anti-ubiquitin antibody. As shown in
Fig. 1A, OAT1 ubiquitination was barely detectable under the
basal condition. Interestingly, PMA treatment induced
a time-dependent ubiquitination of the transporter with
maximum ubiquitination around 15 to 30 minutes. Moreover,
when the immunoblot was reprobed with anti-myc antibody,
it was shown that these short-term treatments did not
produce any major change in the amount of OAT1 (Fig. 1B).
The PMA-induced OAT1 ubiquitination was blocked by
staurosporine, a general PKC inhibitor (Fig. 2A), without
affecting the total amount of OAT1 (Fig. 2B), demonstrating
the specific involvement of PKC in OAT1 ubiquitination. The
ubiquitin-immunoreactive signal displayed a smeary band
centered ∼140 kDa, ∼60 kDa larger than the size of OAT1 (∼80
kDa). Given that each ubiquitin molecule is ∼8 kDa, OAT1
most likely is either multiubiquitinated or polyubiquitinated.
A similar experiment was then performed with rat kidney
slices (Fig. 3). Upon PMA treatment, dramatic increase of
OAT1 ubiquitination was detected. Again, such ubiquitina-
tion was blocked by PKC inhibitor staurosporine (Fig. 3A).
These results suggest that OAT1, regardless of species origin,
undergoes PKC-regulated ubiquitination both in cultured
cells and in rat kidney tissue.
PKC-Induced Ubiquitination of OAT1 by Ectopically
Expressed Ubiquitin. OAT1-expressing cells were tran-
siently transfected with HA-tagged ubiquitin. Transfected
cells were treated with PMA in the presence and absence of
Fig. 1. Time dependence of PMA-induced OAT1 ubiquitination in COS-7
cells. (A) OAT1-expressing COS-7 cells were treated with PKC-activator
PMA (1 mM) for the time periods as indicated. Treated cells were then
lysed, and OAT1 was immunoprecipitated with anti-myc antibody,
followed by immunoblotting (Ib) with anti-ubiquitin antibody. (B) the
same immunoblot as seen in A was reprobed by anti-myc antibody. (C)
densitometry plot of results from (A) as well as from other experiments.
The values are mean 6 S.E. (n = 3).
Fig. 2. PKC specificity of OAT1 ubiquitination in COS-7 cells. (A) OAT1-
expressing COS-7 cells were treated with PKC-activator PMA (1 mM) in
the presence or absence of the PKC-inhibitor staurosporine (St, 2 mM) for
30 minutes. The treated cells were then lysed, and OAT1 was
immunoprecipitated with anti-myc antibody, followed by immunoblotting
(Ib) with anti-ubiquitin antibody. (B) the same immunoblot as seen in (A)
was reprobed by anti-myc antibody. (C) densitometry plot of results from
(A) as well as from other experiments. The values are mean6 S.E. (n = 3).
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PKC inhibitor staurosporine. OAT1 was then immunopreci-
pitated, followed by immunoblotting with anti-HA antibody
(to detect HA-tagged ubiquitin). The HA immunoreactivity
was dramatically increased in the samples treated with PMA,
and was significantly decreased in the presence of stauro-
sporine (Fig. 4A), indicating that the conjugation of HA-
ubiquitin to OAT1 is PKC-dependent.
OAT1 Ubiquitination at the Cell Surface. To deter-
mine whether OAT1 ubiquitination occurs at the cell surface,
we developed a two-step procedure to ensure that only cell-
surface OAT1 ubiquitination was detected (Fig. 5A). Briefly,
cell surface proteins were labeled with or without the
membrane-impermeable reagent NHS-SS-biotin. Labeled
cells were lysed. OAT1 was then immunoprecipitated, with
subsequent streptavidin pull-down to isolate cell surface
OAT1. Immunoblotting of this streptavidin pull-down with
anti-ubiquitin antibody showed no signal for ubiquitin in cells
not labeled with biotin. However, in cells labeled with biotin,
the ubiquitin signal dramatically increased in the presence of
PMA. This result demonstrated that the two-step procedure
detected only cell surface OAT1 ubiquitination.
Using this procedure, we next examined the effect of
a dominant negative mutant of dynamin-2 (Dyn-2m) on
OAT1 ubiquitination. We previously had demonstrated that
OAT1 internalization occurred partly through a Dyn- and
clathrin-dependent pathway and that such internalization
was blocked in cells transfected with a Dyn-2m. As a result,
OAT1 accumulated at the cell surface (Zhang et al., 2008). In
the current experiment, we transfected OAT1-expressing cells
with Dyn-2m (or empty vector as control). Transfected cells
were treated with PMA for 30 minutes, and cell surface
proteins were biotinylated, followed by the same procedure
shown in Fig. 5A for the detection of cell-surface OAT1
ubiquitination. Our results showed that ubiquitinated OAT1
was significantly elevated in cells transfected with Dyn-2m
(Fig. 5, B and C), a maneuver that blocked OAT1 internali-
zation. These data indicate that OAT1 is preferentially
ubiquitinated when present at the cell surface and that
ubiquitination of OAT1 precedes its internalization.
Identification of Ubiquitination Linkage of OAT1. As
mentioned previously, different types of ubiquitination
(mono- versus polyubiquitination via different types of link-
ages) have different physiologic outcomes for the ubiquiti-
nated substrate. To identify the ubiquitination type of OAT1,
we employed a sequential immunoprecipitation procedure to
purify ubiquitinated OAT1. Briefly, we treated OAT1-
expressing cells with the PKC activator PMA for 30 minutes.
Treated cells were then lysed. OAT1 was immunoprecipi-
tated, followed by a second immunoprecipitation using
ubiquitin-specific antibody to purify ubiquitinated OAT1
(normal IgG as negative control). The ubiquitinated OAT1
was then separated on SDS-PAGE, followed by Coomassie
Blue-staining. A Coomassie Blue-stained broad band centered
∼140 kDa was dissected for mass spectrometric analysis, and
a sufficient amount of information regarding the peptides that
originated from ubiquitin sequences was obtained. Among
various peptides identified from ubiquitin, which cover all its
seven lysine residues, only Lys48-linked ubiquitin was
detected (Table 1). These results indicate that OAT1 is
ubiquitinated mainly through Lys48-linked polyubiquitin
chains.
The Role of Lys48-Linked Polyubiquitin Chains in
PKC-Regulated OAT1 Ubiquitination. To explore the
role of Lys48-linked polyubiquitin chains in PKC-regulated
OAT1 ubiquitination, we employed four HA-tagged-ubiquitin
constructs: wild-type ubiquitin Ub; mutant ubiquitin UbDG
(Kolodziejski et al., 2002), which has the C-terminal Gly
residue deleted and therefore prevents the conjugation of
ubiquitin to OAT1; mutant ubiquitin Ub-K48R (Li et al.,
2007), which has the invariant Lys in position 48 mutated to
Arg and prevents the formation of Lys48-linked polyubiquitin
chains; and mutant ubiquitin Ub-K63R (Li et al., 2007), which
has the invariant Lys in position 63 mutated to Arg and
prevents the formation of Lys63-linked polyubiquitin chains.
The cDNA encoding these ubiquitin constructs were trans-
fected into OAT1-expressing cells. The transfected cells were
treated with or without PMA. OAT1 was then immunopreci-
pitated, followed by immunoblotting with anti-HA antibody.
Our results (Fig. 6) showed that PMA treatment resulted in
a strong HA-immunoreactive signal in both Ub- and Ub-
Fig. 3. PKC specificity of OAT1 ubiquitination in the rat kidney. (A) rat
kidney slices were treated with PKC-activator PMA (1 mM) in the presence
or absence of the PKC-inhibitor staurosporine (St, 2 mM) for 30 minutes.
The treated slices were then lysed, and OAT1 was immunoprecipitated
with anti-OAT1 antibody, followed by immunoblotting (Ib) with anti-
ubiquitin antibody P4D1. (B) the same immunoblot as seen in (A) was
reprobed by anti-OAT1 antibody. (C) densitometry plot of results from (A)
as well as from other experiments. Values are mean 6 S.E. (n = 3).
Fig. 4. PMA-induced OAT1 ubiquitination by ectopically expressed
ubiquitin. (A) OAT1-expressing COS-7 cells were transiently transfected
with HA-tagged ubiquitin. The transfected cells were treated with PMA (1
mM) in the presence or absence of the PKC-inhibitor staurosporine (St, 2
mM) for 30 minutes. OAT1 was then immunoprecipitated by anti-myc
antibody, followed by immunoblotting (Ib) with anti-HA antibody. (B) the
same immunoblot as seen in A was reprobed by anti-myc antibody. (C)
densitometry plot of results from (A) as well as from other experiments.
The values are mean 6 S.E. (n = 3).
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K63R-transfected cells, suggesting that a significant amount
of Ub and Ub-K63R was incorporated into OAT1. In contrast,
the same treatment resulted in almost no detection of HA-
immunoreactive signal in both UbDG- and Ub-K48R-
transfected cells. There was no major change in the total
amount of OAT1 immunoprecipitated under these conditions
(not shown). These results strongly support our mass
spectrometric data that majority of OAT1 ubiquitination
consists of Lys48-linked polyubiquitin chains.
The Role of Lys48-Linked Polyubiquitin Chains in
PKC-Regulated OAT1 Surface Expression and Inter-
nalization. We previously had demonstrated that acute
activation of PKC inhibits OAT1 activity by reducing OAT1
surface expression through accelerating internalization of
this transporter from the cell surface to intracellular compart-
ments (Zhang et al., 2008). To explore the role of Lys48-linked
polyubiquitin chains of OAT1 in this process, we examined
PKC-regulated OAT1 surface expression and internalization
in cells transfected with Ub-K48R. As shown in Fig. 7, PMA
treatment resulted in a significant decrease in OAT1 surface
expression in control cells, whereas this PMA effect was
substantially reversed in Ub-K48R-transfected cells. Simi-
larly, PMA treatment resulted in a significant increase in
OAT1 internalization in control cells, whereas this PMA effect
was substantially reversed in Ub-K48R-transfected cells (Fig.
8). These data indicate that Lys48-linked polyubiquitin
chains of OAT1 are essential for PKC-regulated OAT1 surface
expression and internalization.
Discussion
The OAT family mediates the body disposition of a diverse
array of environmental toxins and clinically important drugs.
Therefore, understanding the regulation of these transporters
has profound clinical significance. Short-term (acute) regula-
tion of OAT activity is particularly important when the body
must deal with rapidly changing amounts of substances as
a consequence of variable intake of drugs, fluids, and meals as
well as metabolic activity.
The amount of OATs at the cell surface is critical for their
drug transport activity. We previously had established that
OAT1 undergoes constitutive internalization from and recy-
cling back to the cell surface and that acute activation of PKC
inhibits OAT1 activity by reducing OAT1 cell-surface expres-
sion through accelerating its internalization from the cell
surface to intracellular compartments without affecting the
recycling and the total expression of the transporter (Zhang
et al., 2008). Owing to this characteristic, PKC inhibition of
OAT1 activity is usually moderate (30–50%) because there is
always a certain amount of OAT1 at the cell surface resulting
from the recycling, even with the maximum stimulation of
PKC. In vivo, regulation at such a moderate scale may play an
important role in providing quick and efficient fine-tuning in
the body’s response to environmental changes. However, the
mechanisms underlying PKC-regulated OAT1 trafficking are
largely unknown. In our current study, we provide the first
demonstration that a topology-specific polyubiquitination of
OAT1 plays an essential role in this process.
We first examined OAT1 ubiquitination in COS-7 cells
stably expressing this transporter. Although native systems
that endogenously express transporters are great assets to
identify the endogenous stimuli controlling the transporter
function, heterologous expression systems are useful for
asking mechanistic questions with regard to understanding
the relationship between transporter trafficking and regula-
tion. COS-7 cells offer several useful advantages for study of
the cloned OAT. 1) These cells were directly derived from the
kidney and have been very useful in understanding other
renal transport processes and cellular functions, including
organic cation transport (Nagai et al., 2006; Zhang et al.,
2002). 2) This cell line does not express endogenous OATs.
Therefore, expression of OAT1 in COS-7 cells allows us to
dissect the transport characteristics of OAT1 in a relevant
mammalian systemwithout the possibly confounding effects
of other OATs. 3) They possess endogenous PKC and PKA
signaling pathways and provide a good experimental model
Fig. 5. Cell-surface OAT1 ubiquitination. (A) cell-surface proteins of OAT1-expressing cells were labeled with or without the membrane-impermeable
reagent biotin. The cells were treated with or without PMA for 30 minutes. The labeled cells were lysed. OAT1 was then immunoprecipitated with
subsequent streptavidin pull-down to isolate cell-surface OAT1, followed by immunoblotting with anti-ubiquitin antibody. (B) OAT1-expressing cells
were transfected with the cDNA encoding dominant negative mutant of dynamin-2 (Dyn-2m, empty vector as control). The transfected cells were treated
with PMA (1 mM) for 30 minutes. Cell-surface OAT1 was isolated by cell-surface biotinylation, as described in (A), followed by immunoblotting with anti-
ubiquitin antibody. (C) densitometry plot of results from (B) as well as from other experiments. Surface OAT1 in PMA-treated cells was expressed as the
percentage of surface OAT1 in control cells. The values are mean 6 S.E. (n = 3).
TABLE 1
Ubiquitinated peptides of ubiquitin





aAn asterisk denotes Gly-Gly modification of the amino group of the lysine side
chain.
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system for studying the regulatory mechanisms underlying
many transport processes (Cobb et al., 2002; Kazanietz
et al., 2001). 4) The transport characteristics of OAT1 in
COS-7 cells are in good agreement with those observed in
other systems (Miller, 1998; Shuprisha et al., 2000; Zhang
et al., 2008).
Using these cells, we obtained new data showing that under
basal condition, OAT1 was not significantly ubiquitinated.
However, acute activation of PKC by PMA induced a time-
dependent increase in OAT1 ubiquitination (Fig. 1), and
PMA-induced ubiquitination was blocked by PKC inhibitor
staurosporine (Fig. 2), confirming that this PMA effect is
indeed PKC-dependent. The result was further confirmed
with naturally occurring OAT1 from rat kidney (Fig. 3),
providing the physiologic relevance for our study.
We previously had demonstrated that OAT1 internalizes
partly through a Dyn- and clathrin-dependent pathway and
that such internalization was blocked in cells transfected with
a dominant negative mutant of Dyn-2. As a result, OAT1
accumulated at the cell surface (You et al., 2000). In our
current study, we show (Fig. 5) that blocking OAT1 in-
ternalization with dominant negative mutant of Dyn-2
correlates with the accumulation of ubiquitinated OAT1 in
the plasma membrane, suggesting that ubiquitination is an
early event that occurs at the cell surface before OAT1
internalization.
It has been shown that different types of ubiquitination
(mono- versus polyubiquitination via different types of link-
ages) have different physiologic outcomes for the ubiquiti-
nated substrate. For example, while monoubiquitination is
required for down-regulation of the epidermal growth factor
(EGF) receptor (Haglund et al., 2003a, 2003b), Lys63-linked
ubiquitin chains have been shown to contribute to endocytosis
of the TrkA nerve growth factor receptor (Geetha et al., 2005).
Although IFNAR1 internalization requires both Lys48 and
Lys63 linkages, PRLr internalization relies mainly on Lys63-
conjugated chains (Kumar et al., 2007; Varghese et al., 2008).
To identify the specific types of OAT1 ubiquitination, we
performed mass spectrometric analysis, one of the most
powerful approaches to identify post-translational modifica-
tions of numerous proteins. For this purpose, we developed
sequential immunoprecipitation procedures to ensure that
a high purity of ubiquitinated OAT1 was used. The mass
spectrometric results indeed confirmed that ubiquitin and
OAT1 were the two predominant proteins detected in our
sample, providing evidence that ubiquitin was conjugated to
OAT1 rather than to an OAT1-associated protein. Further-
more, our mass spectrometric analysis identified several
peptide fragments from ubiquitin protein, which covered all
its seven lysine residues. Among these fragments, only Lys48-
linked ubiquitin was detected (Table 1). These results indicate
that OAT1 is ubiquitinated mainly through Lys48-linked
polyubiquitin chains.
The mass spectrometric data that OAT1 was ubiquitinated
mainly through Lys48-linked polyubiquitin chains was indepen-
dently confirmed through the use of a series of ubiquitinmutants
(Fig. 6). The mutant Ub-K63R, which is defective in forming
Lys63-linked polyubiquitin chains, incorporated into OAT1 as
efficiently as that of wild-type ubiquitin, whereas mutant Ub-
K48R, which is defective in forming Lys48-linked polyubiquitin
chains, had the minimum incorporation into OAT1.
The strong evidence of the importance of Lys48-linked
polyubiquitination for OAT1 trafficking came from our
studies using dominant negative ubiquitin mutant Ub-
K48R. Interfering with Lys48-linked polyubiquitination im-
peded the PKC-induced down-regulation of OAT1 surface
Fig. 6. Effects of wild-type ubiquitin and ubiquitin mutants on OAT1
ubiquitination. (A) cDNA for HA-tagged wild-type ubiquitin (Ub),
ubiquitin mutants UbDG, Ub-K48R, and Ub-K63R were transfected into
COS-7 cells, respectively, followed by treatment with or without PMA for
30 minutes. The treated cells were lysed. OAT1 was immunoprecipitated
by anti-myc antibody, followed by immunoblotting with anti-HA antibody.
(B) densitometry plot of results from (A) as well as from other experiments.
Ubiquitinated OAT1 in PMA-treated cells was expressed as the
percentage of that found in control cells. The values are mean 6 S.E.
(n = 3).
Fig. 7. Effect of ubiquitin mutant Ub-K48R on PMA-
regulated OAT1 surface expression. (A) OAT1-expressing
cells were transfected with Ub-K48R (or vector as control),
followed by treatment with or without PMA (1 mM) for 30
minutes. The treated cells underwent cell-surface bio-
tinylation. Biotinylated proteins were isolated with
streptavidin beads and analyzed by immunoblotting with
an anti-myc antibody. (B) densitometry plot of results
from (A) as well as from other experiments. Surface OAT1
in PMA-treated cells was expressed as the percentage of
surface OAT1 in control cells. The values are mean6 S.E.
(n = 3).
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expression (Fig. 7) and the PKC-accelerated OAT1 internal-
ization (Fig. 8).
It is important to note that our entire study investigated the
role of ubiquitination in short-term PKC regulation (PMA
treatment of 30 minutes) on OAT1 trafficking and function.
We had previously demonstrated (Zhang et al., 2008) that
short-term treatment of OAT1-expressing cells with PMA (30
minutes) inhibits OAT1-mediated transport by reducing
OAT1 cell-surface expression through accelerating its in-
ternalization from the cell surface to intracellular compart-
ments without affecting the total expression of the
transporter, suggesting that degradation of OAT1 (through
either proteasome or lysosome) does not happen during the 30
minutes of PMA treatment. This is similar to several other
ubiquitination-regulated proteins for which ubiquitination
regulates endocytosis without affecting their degradation
(Mukhopadhyay and Riezman, 2007). It would be really
interesting to explore, in the future, whether long-term
treatment with PMA (2 to 8 hours) would affect OAT1
degradation.
In conclusion, ubiquitination has been shown to regulate
internalization, postinternalization sorting, and degradation
of other membrane proteins. Our current investigation
focuses on the first step: internalization. The major findings
from our studies are (Fig. 9) that 1) activation of PKC
promotes OAT1 ubiquitination both in vitro and ex vivo, 2)
OAT1 ubiquitinationmainly occurs at the cell surface through
Lys48-linked polyubiquitin chains, and 3) Lys48-linked
polyubiquitination plays an essential role in PKC-regulated
OAT1 trafficking.
To the best of our knowledge, this report is the first
mechanistic study to demonstrate a topology-specific role of
Fig. 8. Effect of ubiquitin mutant Ub-K48R on PMA-regulated OAT1 internalization. (A) COS-7 cells were transfected with OAT1 (1 mg) and Ub-K48R
(4 mg) (or vector as control). OAT1 internalization (15 minutes) was then determined as described under Materials and Methods, followed by
immunoblotting using anti-myc antibody. (B) densitometry plot of results from (A) as well as from other experiments. The internalized surface OAT1 in
PMA-treated cells was expressed as the percentage of internalized surface OAT1 in control cells. The values are mean 6 S.E. (n = 3).
Fig. 9. The role of ubiquitination in OAT1 internalization. Dashed arrows indicate the steps that were not explored in our current study.
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ubiquitination in the regulation of any drug transporters.
What would be the physiologic implication of our studies?
Abnormal OAT1 trafficking may contribute to the impaired
drug elimination in bilateral ureteral obstruction (BUO).
BUO is a serious and common clinical condition, and an
important cause of acute renal failure (Seldin and Giebisch,
2000; Villar et al., 2005). It has been shown (Villar et al., 2005)
that in rats with BUO the elimination of drugs is impaired,
partly due to a redistribution of OAT1 from the cell surface to
the intracellular compartment. In BUO, angiotensin II has an
elevated level of expression (Klahr, 1998; Klahr and Morris-
sey, 2002; Seldin and Giebisch, 2000). We previously reported
that angiotensin II inhibits OAT1 activity through activation
of PKC in cultured cells (Li et al., 2009). Therefore, the high
level of angiotensin II in rats with BUO may inhibit OAT1
activity through PKC-regulated OAT1 ubiquitination and
trafficking. Our current studies may provide important
insight into the molecular, cellular, and clinical bases
underlying BUO.
Finally, while the limited coverage of OAT1-derived
peptides did not allow us to identify the ubiquitin-accepting
lysine residues on OAT1 using mass spectrometry, while the
current manuscript was being reviewed we resorted to
a different approach—site-directed mutagenesis—and we
succeeded in identifying three lysine residues on OAT1 that
serve as ubiquitin acceptors (a separate manuscript has been
submitted). Our work paves the way for the investigation of
the ubiquitin regulation of other OAT isoforms and related
drug transporters.
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